To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma

被引：10

作者：

Bird, Nicholas ^{[1
]}

Scobie, Nicole ^{[2
]}

Palmer, Antonia ^{[3
]}

Ludwinski, Donna ^{[4
]}

机构：

[1] Solving KidsCanc UK, Coram Campus 41 Brunswick Sq, London WC1N 1AZ, England

[2] Zoe4life, Sullens, Switzerland

[3] Kindred Fdn, Oakville, ON, Canada

[4] Solving Kids Canc, New York, NY USA

来源：

PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 08期

关键词：

Neuroblastoma; autologous; stem; cell; transplant; advocate; advocacy; HIGH-RISK NEUROBLASTOMA; CHILDRENS ONCOLOGY GROUP; HIGH-DOSE CHEMOTHERAPY; EVENT-FREE SURVIVAL; METASTATIC NEUROBLASTOMA; RANDOMIZED-TRIAL; MELPHALAN; THERAPY; CONSOLIDATION; BUSULFAN;

D O I：

10.1002/pbc.29663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-dose chemotherapy with autologous stem cell transplant (ASCT) has been a mainstay of high-risk neuroblastoma treatment for several decades, demonstrating improvements in event-free survival but with risks of serious or even life-threatening acute toxicities, severe long-term adverse health effects for survivors, and ongoing contention regarding overall survival benefit. The merits of ASCT in the modern era of immunotherapy are a source of debate among parents, advocates, and some physicians. Here we examine evidence for and against ASCT, explore parent attitudes and their turmoil over decision-making, and strongly encourage international research consortia to develop a coordinated strategy to accelerate progress toward a future that avoids the routine use of ASCT in high-risk neuroblastoma.

引用

页数：8

共 66 条

[1]

[Anonymous], HIGH RISK NEUR STUD

[2]

[Anonymous], 2014, J CLIN ONCOL, V32, P1862, DOI [10.1200/jco.2014.57.0382, DOI 10.1200/JCO.2014.57.0382]

[3] Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision Medicine [J].

Bagatell, Rochelle ;

Irwin, Meredith S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (08) :729-731

[4] Factors associated with recurrence and survival length following relapse in patients with neuroblastoma [J].

Basta, Nermine O. ;

Halliday, Gail C. ;

Makin, Guy ;

Birch, Jillian ;

Feltbower, Richard ;

Bown, Nick ;

Elliott, Martin ;

Moreno, Lucas ;

Barone, Giuseppe ;

Pearson, Andrew D. J. ;

James, Peter W. ;

Tweddle, Deborah A. ;

McNally, Richard J. Q. .

BRITISH JOURNAL OF CANCER, 2016, 115 (09) :1048-1057

[5] Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) [J].

Bellini, Angela ;

Poetschger, Ulrike ;

Bernard, Virginie ;

Lapouble, Eve ;

Baulande, Sylvain ;

Ambros, Peter F. ;

Auger, Nathalie ;

Beiske, Klaus ;

Bernkopf, Marie ;

Betts, David R. ;

Bhalshankar, Jaydutt ;

Bown, Nick ;

de Preter, Katleen ;

Clement, Nathalie ;

Combaret, Valerie ;

de Mora, Jaime Font ;

George, Sally L. ;

Jimenez, Irene ;

Jeison, Marta ;

Marques, Barbara ;

Martinsson, Tommy ;

Mazzocco, Katia ;

Morini, Martina ;

Muehlethaler-Mottet, Annick ;

Noguera, Rosa ;

Pierron, Gaelle ;

Rossing, Maria ;

Taschner-Mandl, Sabine ;

Van Roy, Nadine ;

Vicha, Ales ;

Chesler, Louis ;

Balwierz, Walentyna ;

Castel, Victoria ;

Elliott, Martin ;

Kogner, Per ;

Laureys, Genevieve ;

Luksch, Roberto ;

Malis, Josef ;

Popovic-Beck, Maja ;

Ash, Shifra ;

Delattre, Olivier ;

Valteau-Couanet, Dominique ;

Tweddle, Deborah A. ;

Ladenstein, Ruth ;

Schleiermacher, Gudrun .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (30) :3377-+

[6] Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial [J].

Berthold, F ;

Boos, J ;

Burdach, S ;

Erttmann, R ;

Henze, G ;

Hermann, J ;

Klingebiel, T ;

Kremens, B ;

Schilling, FH ;

Schrappe, M ;

Simon, T ;

Hero, B .

LANCET ONCOLOGY, 2005, 6 (09) :649-658

[7] Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation [J].

Berthold, Frank ;

Ernst, Angela ;

Hero, Barbara ;

Klingebiel, Thomas ;

Kremens, Bernhard ;

Schilling, Freimut H. ;

Simon, Thorsten .

BRITISH JOURNAL OF CANCER, 2018, 119 (03) :282-290

[8] Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015 [J].

Berthold, Frank ;

Spix, Claudia ;

Kaatsch, Peter ;

Lampert, Fritz .

PEDIATRIC DRUGS, 2017, 19 (06) :577-593

[9] When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma comment [J].

Bird, Nicholas ;

Knox, Leona ;

Palmer, Antonia ;

Heenen, Delphine ;

Blanc, Patricia ;

Scobie, Nicole ;

Ludwinski, Donna .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) :120-+

[10] Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma [J].

Bona, Kira ;

Li, Yimei ;

Winestone, Lena E. ;

Getz, Kelly D. ;

Huang, Yuan-Shung ;

Fisher, Brian T. ;

Desai, Ami, V ;

Richardson, Troy ;

Hall, Matt ;

Naranjo, Arlene ;

Henderson, Tara O. ;

Aplenc, Richard ;

Bagatell, Rochelle .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (03) :282-291

← 1 2 3 4 5 6 7 →